SEC Form 4 · accession 0001000229-19-000004
CORE LABORATORIES N V · CLB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Demshur
Officer — Chief Executive Officer · Director
Period of report
Dec 31, 2018
Accepted (ET)
Jan 3, 2019 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001000229
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Dec 31, 2018 | M | 52,995 | $0.00 | A | 344,358 | D | |
| Common Shares | Dec 31, 2018 | F | 18,340 | $59.66 | D | 326,018 | D | |
| Common Shares | holding | — | — | — | 68,530 | I | 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance SharesF1 | $0.00 | Dec 31, 2018 | M | 52,995 | D | — | — | Common Shares | 52,995 | 0 | D |
Explanation of responses
- F1The shares vesting were awarded as restricted performance shares in February 2016 as reported in the Form 4 filing on February 16, 2016. This filing states that 80% of the restricted performance shares will vest only upon the Company's return on invested capital being in the top decile among the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period, with the remaining 20% vesting if the Company is the top ROIC performer. The Company was the top performing ROIC company as of the end of the performance period and as such the performance criteria and all requirements for full vesting have been met and thus 100% of the shares vested on December 31, 2018, at the conclusion of the performance period.